Antje Wick

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7190968/publications.pdf

Version: 2024-02-01

53 papers	4,716 citations	159585 30 h-index	214800 47 g-index
53 all docs	53 docs citations	53 times ranked	6589 citing authors

#	Article	IF	Citations
1	Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma. JAMA Oncology, 2020, 6, 1003.	7.1	805
2	Radiomic Profiling of Glioblastoma: Identifying an Imaging Predictor of Patient Survival with Improved Performance over Established Clinical and Radiologic Risk Models. Radiology, 2016, 280, 880-889.	7.3	345
3	Novel, improved grading system(s) for IDH-mutant astrocytic gliomas. Acta Neuropathologica, 2018, 136, 153-166.	7.7	298
4	Automated brain extraction of multisequence MRI using artificial neural networks. Human Brain Mapping, 2019, 40, 4952-4964.	3.6	284
5	Automated quantitative tumour response assessment of MRI in neuro-oncology with artificial neural networks: a multicentre, retrospective study. Lancet Oncology, The, 2019, 20, 728-740.	10.7	271
6	MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial. Clinical Cancer Research, 2015, 21, 2057-2064.	7.0	264
7	Radiogenomics of Glioblastoma: Machine Learningâ€“based Classification of Molecular Characteristics by Using Multiparametric and Multiregional MR Imaging Features. Radiology, 2016, 281, 907-918.	7.3	236
8	A vaccine targeting mutant IDH1 in newly diagnosed glioma. Nature, 2021, 592, 463-468.	27.8	232
9	Next-generation sequencing in routine brain tumor diagnostics enables an integrated diagnosis and identifies actionable targets. Acta Neuropathologica, 2016, 131, 903-910.	7.7	203
10	Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial. Lancet Oncology, The, 2022, 23, 53-64.	10.7	165
11	Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter. Neuro-Oncology, 2022, 24, 1935-1949.	1.2	165
12	Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide. Neuro-Oncology, 2016, 18, now133.	1.2	130
13	Treatment of glioblastoma in adults. Therapeutic Advances in Neurological Disorders, 2018, 11, 175628641879045.	3.5	117
14	Phase II Study of Radiotherapy and Temsirolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without MGMT Promoter Hypermethylation (EORTC 26082). Clinical Cancer Research, 2016, 22, 4797-4806.	7.0	105
15	N2M2 (NOA-20) phase I/II trial of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed non-MGMT hypermethylated glioblastoma. Neuro-Oncology, 2019, 21, 95-105.	1.2	100
16	Pseudoprogression in patients with glioblastoma: clinical relevance despite low incidence. Neuro-Oncology, 2015, 17, 151-159.	1.2	90
17	Relative cerebral blood volume is a potential predictive imaging biomarker of bevacizumab efficacy in recurrent glioblastoma. Neuro-Oncology, 2015, 17, 1139-1147.	1.2	89
18	VXM01 phase I study in patients with progressive glioblastoma: Final results.. Journal of Clinical Oncology, 2018, 36, 2017-2017.	1.6	87

#	Article	IF	Citations
19	Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p/19q co-deletion (TAVAREC): a randomised controlled phase 2 EORTC trial. Lancet Oncology, The, 2018, 19, 1170-1179.	10.7	80
20	Phase 1b/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma. Investigational New Drugs, 2020, 38, 1570-1579.	2.6	70
21	Current status and future directions of anti-angiogenic therapy for gliomas. Neuro-Oncology, 2016, 18, 315-328.	1.2	61
22	Glioma cell VEGFR-2 confers resistance to chemotherapeutic and antiangiogenic treatments in PTEN-deficient glioblastoma. Oncotarget, 2015, 6, 31050-31068.	1.8	52
23	Deep-learning-based synthesis of post-contrast T1-weighted MRI for tumour response assessment in neuro-oncology: a multicentre, retrospective cohort study. The Lancet Digital Health, 2021, 3, e784-e794.	12.3	52
24	MR Perfusionâ€“derived Hemodynamic Parametric Response Mapping of Bevacizumab Efficacy in Recurrent Glioblastoma. Radiology, 2016, 279, 542-552.	7.3	51
25	Superiority of temozolomide over radiotherapy for elderly patients with RTK II methylation class, MGMT promoter methylated malignant astrocytoma. Neuro-Oncology, 2020, 22, 1162-1172.	1.2	42
26	Quantitative Dynamic Oxygen 17 MRI at 7.0 T for the Cerebral Oxygen Metabolism in Glioma. Radiology, 2020, 295, 181-189.	7.3	37
27	Clinical parameters outweigh diffusion- and perfusion-derived MRI parameters in predicting survival in newly diagnosed glioblastoma. Neuro-Oncology, 2016, 18, 1673-1679.	1.2	36
28	Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid Tumors. Clinical Cancer Research, 2021, 27, 2723-2733.	7.0	33
29	Assessment of tumor oxygenation and its impact on treatment response in bevacizumab-treated recurrent glioblastoma. Journal of Cerebral Blood Flow and Metabolism, 2017, 37, 485-494.	4.3	32
30	Feasibility of real-time molecular profiling for patients with newly diagnosed glioblastoma without MGMT promoter hypermethylationâ€”the NCT Neuro Master Match (N2M2) pilot study. Neuro-Oncology, 2018, 20, 826-837.	1.2	32
31	A mutation-specific peptide vaccine targeting IDH1R132H in patients with newly diagnosed malignant astrocytomas: A first-in-man multicenter phase I clinical trial of the German Neurooncology Working Group (NOA-16).. Journal of Clinical Oncology, 2018, 36, 2001-2001.	1.6	21
32	Methylome analyses of three glioblastoma cohorts reveal chemotherapy sensitivity markers within DDR genes. Cancer Medicine, 2020, 9, 8373-8385.	2.8	19
33	Noninvasive Characterization of Tumor Angiogenesis and Oxygenation in Bevacizumab-treated Recurrent Glioblastoma by Using Dynamic Susceptibility MRI: Secondary Analysis of the European Organization for Research and Treatment of Cancer 26101 Trial. Radiology, 2020, 297, 164-175.	7.3	19
34	Tryptophan metabolism is inversely regulated in the tumor and blood of patients with glioblastoma. Theranostics, 2021, 11, 9217-9233.	10.0	16
35	Assessment of CAR T Cell Frequencies in Axicabtagene Ciloleucel and Tisagenlecleucel Patients Using Duplex Quantitative PCR. Cancers, 2020, 12, 2820.	3.7	13
36	Prophylactic anticoagulation in patients with glioblastoma or brain metastases and atrial fibrillation: an increased risk for intracranial hemorrhage?. Journal of Neuro-Oncology, 2021, 152, 483-490.	2.9	13

#	Article	IF	Citations
37	Validation of diffusion MRI phenotypes for predicting response to bevacizumab in recurrent glioblastoma: post-hoc analysis of the EORTC-26101 trial. Neuro-Oncology, 2020, 22, 1667-1676.	1.2	9
38	MGMT promoter methylation as a prognostic biomarker for benefit from dose-intensified temozolomide rechallenge in progressive glioblastoma: First results from the randomized phase II DIRECTOR trial.. Journal of Clinical Oncology, 2014, 32, 2015-2015.	1.6	6
39	Impact of tapering and discontinuation of bevacizumab in patients with progressive glioblastoma. Journal of Neuro-Oncology, 2016, 129, 533-539.	2.9	5
40	Nonmeasurable Speckled Contrast-Enhancing Lesions Appearing During Course of Disease Are Associated With IDH Mutation in High-Grade Astrocytoma Patients. International Journal of Radiation Oncology Biology Physics, 2018, 102, 1472-1480.	0.8	5
41	Abstract CT025: Dabrafenib plus trametinib in BRAF V600E-mutant high-grade (HGG) and low-grade glioma (LGG). , 2021, , .		5
42	Umbrella protocol for phase I/IIa trials of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed glioblastoma without MGMT promoter methylation Neuro Master Match (NÂ²MÂ²).. Journal of Clinical Oncology, 2016, 34, TPS2084-TPS2084.	1.6	4
43	VXM01 phase I study in patients with resectable progression of a glioblastoma.. Journal of Clinical Oncology, 2017, 35, 2061-2061.	1.6	4
44	Molecular genetic, host-derived and clinical determinants of long-term survival in glioblastoma: First results from the ETERNITY study (EORTC 1419).. Journal of Clinical Oncology, 2019, 37, 2056-2056.	1.6	3
45	Prognostic Significance of DNA Methylation Profiles at MRI Enhancing Tumor Recurrence: a Report from the EORTC 26091 TAVAREC Trial. Clinical Cancer Research, 2022, 28, 2440-2448.	7.0	3
46	Location and Volume of MRI Artifacts in Patients With Implanted Sphenopalatine Ganglion Neurostimulators for Treatment of Chronic Cluster Headache. Neuromodulation, 2019, 22, 978-985.	0.8	2
47	Oral DNA vaccination targeting VEGFR2 combined with anti-PDL1 avelumab in patients with progressive glioblastoma: Safety run-in resultsâ€"NCT03750071.. Journal of Clinical Oncology, 2020, 38, 3001-3001.	1.6	2
48	Lung toxicity of CCNU in the treatment of progressive gliomas. Neuro-Oncology Advances, 0, , .	0.7	2
49	ID(H)entifying checkpoint inhibitor candidates among diffuse glioma. Neuro-Oncology, 2017, 19, 1427-1428.	1.2	1
50	ACTR-23. MOLECULAR GENETIC, HOST-DERIVED AND CLINICAL DETERMINANTS OF LONG-TERM SURVIVAL IN GLIOBLASTOMA: FIRST RESULTS FROM THE BRAIN TUMOR FUNDERSâ€™ COLLABORATIVE CONSORTIUM. Neuro-Oncology, 2017, 19, vi5-vi6.	1.2	0
51	Towards a molecular algorithm predicting glioma treatment response and resistance: A biomarker analysis and path to real time profiling in N2M2.. Journal of Clinical Oncology, 2018, 36, 12090-12090.	1.6	0
52	Oral DNA vaccination targeting VEGFR-2 combined with anti-PD-L1 avelumab in patients with progressive glioblastoma, a phase I/II study: NCT03750071.. Journal of Clinical Oncology, 2019, 37, TPS2076-TPS2076.	1.6	0
53	Impact of predictive impact of MGMT promoter methylation in malignant astrocytomas depends on the methylation subgroup.. Journal of Clinical Oncology, 2019, 37, 2013-2013.	1.6	0